On August 16, 2019, Samuel Agresta, M.D., M.P.H., Chief Medical Officer of Infinity Pharmaceuticals, Inc. (the Company) and a named executive officer of the Company, notified the Company of his decision to resign effective September 13, 2019. Dr. Agresta confirmed that he is not resigning as a result of any dispute or disagreement with the Company. On August 20, 2019, the company's Board of Directors, based on the recommendation of the Nominating and Corporate Governance Committee of its Board, elected Samuel Agresta, M.D., M.P.H., as a director to fill a vacancy on Board and appointed Dr. Agresta to the Research and Development Committee (the R&D Committee). His term will begin on October 16, 2019 (the Commencement Date) and will expire at 2020 annual meeting of stockholders or his earlier death, resignation, or removal.